Search Results 2301-2310 of 13403 for monoclonal antibody

  1. Meningococcal vaccine (intramuscular route, subcutaneous route) - Side effects & uses - Mayo Clinic

    The vaccine works by causing your body to produce its own protection (antibodies) against the disease. Bexsero® and Trumenba® is active against group B ...

  2. Clinical trials - Oncology (Medical)

    This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and ...

  3. Clinical trials - Oncology (Medical)

    For various rare immunobullous diseases, detection of a circulating autoantibody is necessary for accurate diagnosis. As a CLIA requirement, every clinical ...

  4. Clinical trials - Oncology (Medical)

    For various rare immunobullous diseases, detection of a circulating autoantibody is necessary for accurate diagnosis. As a CLIA requirement, every clinical ...

  5. CAR-T cell therapy - Doctors & Departments - Mayo Clinic

    yeloma, POEMS syndrome, Waldenstrom macroglobulinemia, Monoclonal gammopathy of undetermined significance, Plasma cell disorders, AL amyloidosis. Show more ...

  6. A Study To Evaluate The Clinical Utility For The Ion™ Endoluminal System

    Subjects taking the following medications: Immunosuppressive treatment with systemic azathioprine, Cyclosporine, antibodies or cytostatics, other ...

  7. A Study To Evaluate Expanded Access To Mepolizumab For Patients With Hypereosinophilic Syndrome - Mayo Clinic

    Patients with history of serious allergic reaction (hypersensitivity/anaphylaxis) to anti-IL5 or other antibody therapy or known or suspected ...

  8. Master Protocol To Assess The Safety And Dose Of First Time In Human Next Generation Engineered T Cells In NY-ESO-1 And/or LAGE-1a Positive Advanced Solid Tumors - Mayo Clinic

    Previous NY-ESO-1 vaccine or NY-ESO-1 targeting antibody. Prior gene therapy using an integrating vector. Previous allogeneic hematopoietic stem cell ...

  9. Clinical trials - Oncology (Medical)

    This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and ...

  10. Medical Research & Education - Mayo Clinic News Network

    ROCHESTER, Minn. — A new Mayo Clinic study published in the New England Journal of Medicine has uncovered that an off-the-shelf, dual-antibody therapy can ...